Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib in RDEB-associated SCC
NCT04177498Phase 1Completed
- Sponsor
- Thomas Jefferson University
- Start
- Aug 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rigosertib in squamous cell carcinoma (SCC), sponsored by Thomas Jefferson University. Primary endpoints: Overall Response Rate at 12 months and Incidence of treatment-related adverse events at 12 months. Started Aug 2021; status: completed.
02
Drugs
rigosertib
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT04177498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177498.